Published in Blood on September 10, 2012
The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol (2015) 1.52
Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother (2013) 1.31
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One (2012) 1.04
Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Front Immunol (2014) 1.04
Human plasmacytoid dendritic cells: from molecules to intercellular communication network. Front Immunol (2013) 0.99
Skin-resident antigen-presenting cells: instruction manual for vaccine development. Front Immunol (2013) 0.94
CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology (2013) 0.93
Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology (2013) 0.91
Communication between Human Dendritic Cell Subsets in Tuberculosis: Requirements for Naive CD4(+) T Cell Stimulation. Front Immunol (2014) 0.90
Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int (2014) 0.87
Crosstalk between human DC subsets promotes antibacterial activity and CD8+ T-cell stimulation in response to bacille Calmette-Guérin. Eur J Immunol (2013) 0.87
Characterization of CD56+ dendritic-like cells: a normal counterpart of blastic plasmacytoid dendritic cell neoplasm? PLoS One (2013) 0.84
Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy. Crit Rev Immunol (2013) 0.82
Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology. Clin Immunol (2014) 0.82
B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21. Int Immunol (2014) 0.81
mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother (2013) 0.80
Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells. Front Immunol (2013) 0.79
Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection. Vaccines (Basel) (2013) 0.78
Dendritic Cell Immune Responses in HIV-1 Controllers. Curr HIV/AIDS Rep (2017) 0.78
Gut-Associated Plasmacytoid Dendritic Cells Display an Immature Phenotype and Upregulated Granzyme B in Subjects with HIV/AIDS. Front Immunol (2015) 0.77
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells. Cancer Immunol Immunother (2014) 0.77
HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med (2014) 0.77
Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo. Exp Hematol Oncol (2013) 0.76
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J Hematol Oncol (2016) 0.76
A subset of human plasmacytoid dendritic cells expresses CD8α upon exposure to herpes simplex virus type 1. Front Microbiol (2015) 0.76
Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep (2017) 0.75
A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery. Oncotarget (2016) 0.75
Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology (2016) 0.75
Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy. Oncotarget (2017) 0.75
CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front Immunol (2017) 0.75
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res (2004) 2.06
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Myosin II and mechanotransduction: a balancing act. Trends Cell Biol (2007) 1.85
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood (2011) 1.83
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
How C-type lectins detect pathogens. Cell Microbiol (2005) 1.77
Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem (2002) 1.71
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 1.60
Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A (2009) 1.60
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol (2003) 1.53
Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem (2008) 1.50
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol (2004) 1.48
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
The heme-heme oxygenase system: a molecular switch in wound healing. Blood (2003) 1.39
The small GTPase Rap1 is required for Mn(2+)- and antibody-induced LFA-1- and VLA-4-mediated cell adhesion. J Biol Chem (2002) 1.39
A critical role for prostaglandin E2 in podosome dissolution and induction of high-speed migration during dendritic cell maturation. J Immunol (2006) 1.37
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol (2012) 1.34
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood (2012) 1.34
Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology (2008) 1.33
TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation. J Mol Biol (2008) 1.32
Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release (2010) 1.32
Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood (2005) 1.30
Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum (2005) 1.29
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
Organization of the integrin LFA-1 in nanoclusters regulates its activity. Mol Biol Cell (2006) 1.26
Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res (2006) 1.26
Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol (2010) 1.24
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
Functional assessment of human dendritic cells labeled for in vivo (19)F magnetic resonance imaging cell tracking. Cytotherapy (2010) 1.23
DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J Leukoc Biol (2008) 1.22
Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood (2012) 1.21
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
Massive autophosphorylation of the Ser/Thr-rich domain controls protein kinase activity of TRPM6 and TRPM7. PLoS One (2008) 1.19
PGE2-mediated podosome loss in dendritic cells is dependent on actomyosin contraction downstream of the RhoA-Rho-kinase axis. J Cell Sci (2008) 1.18
Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials (2010) 1.18
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol (2008) 1.15
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Lateral mobility of individual integrin nanoclusters orchestrates the onset for leukocyte adhesion. Proc Natl Acad Sci U S A (2012) 1.15
Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev (2010) 1.14
Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother (2002) 1.12
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther (2008) 1.11
Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells. Nano Lett (2007) 1.10
Nanoscale organization of the pathogen receptor DC-SIGN mapped by single-molecule high-resolution fluorescence microscopy. Chemphyschem (2007) 1.10
Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol (2013) 1.09
The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum. J Leukoc Biol (2004) 1.09
Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol (2007) 1.08
Interlaboratory round robin on cantilever calibration for AFM force spectroscopy. Ultramicroscopy (2011) 1.08
Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One (2009) 1.07
The alpha-kinases TRPM6 and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC. FEBS Lett (2008) 1.07
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood (2010) 1.07
Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines. Semin Immunol (2011) 1.06
Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood (2011) 1.06